islatravir (MK-8591) / Merck (MSD)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
islatravir (MK-8591) / Merck (MSD)
DRIVE2Simplify, NCT03272347: Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Completed
2b
123
Europe, US, RoW
Islatravir, MK-8591, Placebo to Islatravir, Doravirine, MK-1439, Placebo to Doravirine, Lamivudine, 3TC, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, MK-1439A, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir, MK-8591A
Merck Sharp & Dohme LLC
HIV-1 Infection
03/21
03/22
NCT04003103: Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

Completed
2a
242
US, RoW
Islatravir, MK-8591, Placebo
Merck Sharp & Dohme LLC
HIV-1 Infection
03/22
11/22
2020-003071-18: Dose Ranging, Switch Study of ISL and MK-8507 Once-Weekly

Not yet recruiting
2
140
Europe
Islatravir, MK-8507, MK-8591, MK-8507, Capsule, Tablet, Film-coated tablet, Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
HIV-1 infection, HIV-1 infection, Diseases [C] - Virus Diseases [C02]
 
 
2017-000437-32: Dose Ranging Trial of MK-8591 Given in Combination with Doravirine (DOR) and Lamivudine (3TC)

Not yet recruiting
2
120
Europe
MK-8591, Doravirine, Doravirine/Lamivudine/Tenofovir disoproxil fumarate, Epivir, MK-8591A, MK-8591, MK-1439, MK-1439A, MK-8591A, Capsule, Film-coated tablet, Epivir
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
HIV-1 infection, HIV-1 infection, Diseases [C] - Virus Diseases [C02]
 
 
MK-8591-013, NCT04564547: Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) []

Active, not recruiting
2
161
Europe, US
Islatravir, MK-8591, Ulonivirine, MK-8507, BIC/FTC/TAF, BIKTARVY®, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF
Merck Sharp & Dohme LLC
HIV-1 Infection
12/24
12/24
NCT05052996: Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

Active, not recruiting
2
142
US
ISL, LEN, GS-6207, B/F/TAF, Biktarvy®
Gilead Sciences, Merck Sharp & Dohme LLC
HIV-1 Infection
12/23
11/27
MK-8591-035, NCT05130086: A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants

Withdrawn
2
0
NA
Islatravir, MK-8591
Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV) Infections
03/24
03/24
MK-8591-043, NCT05115838: Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Withdrawn
2
175
NA
Islatravir, MK-8591, Placebo
Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, HIV
10/25
10/25

Download Options